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Abstract
A phospholipase inhibitor (WSG) has been purified from Withania somnifera using gel-filtration and ion-exchange chroma-
tographies. The WSG is an acidic glycoprotein. Its molecular mass as determined by SDS–PAGE was 27 kDa. It neutralized the
enzyme activity and pharmacological properties such as cytotoxicity, edema, and myotoxicity of a multi-toxic Indian cobra venom
phospholipase (NNXIa–PLA) but failed to neutralize the neurotoxicity. The glycan part of the molecule does not appear to be
involved in any of the pharmacological properties studied. The results suggest that the neutralization of the pharmacological effects
of the toxic phospholipase is brought about by inhibition of the enzyme activity by formation of a complex between the WSG and
the toxic phospholipase. We report the purification and characterization of a glycoprotein phospholipase A inhibitor fromWithania
somnifera, medicinal plant.
 2002 Elsevier Science (USA). All rights reserved.
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There has been a tremendous growth in the search for
alternative therapies and the therapeutic use of natural
products, especially those derived from plants [1,2].
Plant sources have provided inspiration in the develop-
ment of an impressive number of synthetic drugs. These
resources provide a host of novel chemical compounds
to yield therapeutic agents, which have been optimized
on the basis of their biological activities. The most ef-
fective and accepted therapy for snakebite patients is
immediate administration of specific or polyvalent an-
tivenom following envenomation. Unfortunately varia-
tion in venom composition from one region to another
renders it ineffective [3]. Antivenoms also carry an as-
sociated risk of anaphylaxis and serum reactions [4,5]
and may not always prevent the local effects of enven-
omation such as myonecrosis, hemorrhage, and edema
[6]. The use of plant extracts as antidotes for snake ve-
nom not only is common in places where they do not
have prompt access to serum therapy but also is used as
an adjunct to antivenin therapy. A number of plants
with antidotal properties have been reported [7,8]. The
plant isolates have become an attractive research mate-
rial as an alternative for antiserum. A number of crude
extracts and purified compounds have been reported to
be active against snakebite [7,9,10]. The extracts are
mixtures of several active compounds that neutralize the
toxic properties of the venom. Such studies are not
useful in understanding the mode of action of active
compounds. The active compounds structurally resem-
ble the secondary metabolites and this similarity is the
basis for their physiological action. The activity may be
attributed to the presence of enzymatic inhibitors,
chemical inactivators, or immunomodulators present in
the plant isolates [11]. Guerranti et al. [12] demonstrated
that the presence of proteins from seed extract of Mu-
cuna pruiens protected mice against the toxic effects of
Echis carinatus venom. It does so by an immunological
mechanism based on a series of specific epitopes com-
mon to some vegetal and venom proteins. Generally, the
active compounds are multifunctional and possess more
than one biochemical/pharmacological property. Inter-
action of such compounds with the toxins/enzymes
leads to the neutralization/inhibition of their activities.
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Lombardo and Dennis [13] demonstrated that Manoa-
lide, a nonsteroidal sesterterpenoid isolated from
sponge, inhibits cobra venom phospholipase activity.
Snake venoms are complex mixtures of proteins and
peptides. Venoms of elapids mainly constitute a-neuro-
toxins, cardiotoxins and phospholipases which are the
main factors involved in the toxic pharmacology and
lethality of the venom [14]. Phospholipases, besides
playing a digestive role in phospholipid hydrolysis, exert
a wide variety of pharmacological activities such as
neurotoxicity, cardiotoxicity, anticoagulant effect, inhi-
bition of platelet aggregation, cytotoxicity, and edema-
inducing activity [15–17].
Withania somnifera (Ashwaganda) is ethanobotani-
cally reputed to be an antiulcer, antihepatotoxic, anti-
inflammatory, antitumor, immunomodulator and is
reported to be active against scorpion bite [18–21].
Earlier studies have shown that aqueous extracts of
W. somnifera inhibit the phospolipase activity of Naja
naja venom and increase the survival time of mice in-
jected with the lethal dose. The present investigation
reports isolation and characterization of an active gly-
coprotein (WSG)1 fromW. somnifera, which neutralized
the pharmacological effects induced by the basic phos-
pholipase for the first time.
Materials and methods
Withania somnifera roots were purchased from Pan-
sari, Shivrampet, Mysore, India. The roots were au-
thenticated at the herbarium in the department of
taxonomy at the Ayurveda Medical College, Mysore,
India. Indian cobra (N. naja) venom (pooled and ly-
ophilized from four to six adult snakes of both the sexes)
was purchased from Hindustan Park (Kolkota, West
Bengal). The NNXIa-PLA was purified by a combina-
tion of ion-exchange and gel-filtration chromatogra-
phies (data not shown). Male Swiss Wistar mice
weighing 20–22 g obtained from the Central Animal
House Facility (Department of Zoology, University of
Mysore, Mysore, India) were used for the pharmaco-
logical studies. The animal care and handling were
conducted in compliance with the National Regulation
for Animal Research. The animal experiments were
carried out after review of the protocols by the Animal
Ethical Committee of the University of Mysore.
Purification of WSG
Withania somnifera roots were washed, shade dried,
and powdered. One hundred grams of the powdered
root was mixed well with 400ml of 0.1M citrate phos-
phate buffer, pH 6.8, and left overnight at 4 C. The
supernatant (140ml) was filtered and concentrated to
40ml by lyophilization (crude extract). The crude ex-
tract (180mg BSA equivalent) was loaded on to a
Sephadex G-50 (Pharmacia) column (1:4 73cm) pre-
equilibrated with 0.1M NaCl and eluted in the same
solution. The flow rate was adjusted to 30ml/h and 3-ml
fractions were collected using a Frac-100 automatic
fraction collector (LKB, Bromma, Sweden). Protein
elution was monitored at 280 nm using a Shimadzu 1601
A spectrophotometer. The pooled fraction of peak 1
(WSI) from the Sephadex G-50 column (Fig. 1A) was
applied onto a DEAE–Sephadex A-25 (Pharmacia)
column (1:4 35cm) preequilibrated with 0.01M Tris–
HCl buffer, pH 6.0. Elution was carried out using a
stepwise gradient of NaCl (0.1, 0.2, 0.3, 0.4, 0.5, and
1M) in 0.1M Tris–HCl buffer, pH 6.0, as shown in Fig.
1B. Fractionation was carried out at 20 C. The flow
rate was adjusted to 25ml/h and 2.5-ml fractions were
collected using a Frac-100 automatic fraction collector
(LKB, Bromma, Sweden). Protein elution was moni-
tored at 280 nm using a spectrophotometer. Individual
fractions of the protein peaks were pooled, desalted,
lyophilized, and stored at )18 C. The pooled fractions
of the third peak (WD3) from the DEAE–Sephadex A-
25 column (Fig. 1B) was rechromatographed on the
same column (1 50cm) prequiliberated with 0.01M
Tris–HCl buffer, pH 6.0. The column was loaded with
WD3 (6.3mg) in the same buffer. Elution was carried
out stepwise using NaCl gradient in 0.01M Tris–HCl
buffer, pH 6.0 (0.1, 0.2, and 0.5M) as shown in Fig. 1C.
Fractionation was carried out at 20 C at a flow rate of
20ml/h and 2-ml fractions were collected using a Frac-
100 automatic fraction collector (LKB, Bromma, Swe-
den). It resolved into two peaks, WSG and WSG1.
RP-HPLC of WSG. The HPLC system (Shimadzu)
consisted of a two-solvent delivery system, and a vari-
able wavelength detector controlled with a solvent pro-
grammer was used. Solvent A contained 0.1%
trifluoroacetic acid (TFA) in water and solvent B con-
tained 0.1% TFA in acetonitrile. The column was wa-
shed with solvent A for 5min. WSG (20 lg in 50 ll of
water) was loaded onto a Shim-Pak (ODS) C18, (10 lm,
0:46 25cm) column, preequilibrated with solvent A.
The bound protein was eluted by a linear gradient of
acetonitrile (0–100%) at a flow rate of 1ml/min. The
elution profile was monitored at 280 nm for 45min.
Protein was estimated by the method of Lowry et al. [22]
using bovine serum albumin (BSA) as standard.
Determination of carbohydrate content by total
sugar estimations. Carbohydrate content in WSG was
1 Abbreviations used: PLA, phospholipase A; WSG, Withania
somnifera glycoprotein; BSA, bovine serum albumin; TFA, trifluro-
acetic acid; PAS, periodic acid Schiffs stain; ODS, octadodecyl sulfate;
EAT, Ehrlich ascites tumor; PBS, phosphate-buffered saline; CVV
myotoxin, Crotalus viridis viridis myotoxin; ACL myotoxin, Akistr-
odon contortrix lasticintus myotoxin; LDH, lactate dehydrogenase;
CPK, creatine phosphokinase; GLC, gas–liquid chromatography;
PLIs, phospholipase inhibitors.
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determined by the phenol–sulfuric acid method [23].
Glucose (0–25 lg) was used as reference standard.
Determination of amino sugars. Amino sugars in
WSG were determined by the colorimetric method of
Ludoweig and Benmaman [24]. Glucosamine hydro-
chloride (0–50 lg) was used as reference standard.
Estimation of phenolic compounds. Phenolic com-
pounds in WSG were determined by the colorimetric
method as described by Swain and Hillis [25]. Phenol (0–
40 lg) was used as reference standard.
PAGE and SDS–PAGE of WSG. PAGE was carried
out for crude extract, WSI, WD3, and WSG on 10%
polyacrylamide gel using Tris–glycine buffer (pH 6.8)
according to the method of Davis [26]. The gels were
stained with Coomassie brilliant blue R-250. SDS–
PAGE (12.5%) was carried out according to the method
of Laemmli [27] under reduced conditions. Crude ex-
tract, WSI, WSG, and low-molecular-weight markers
(Sigma Chemicals) were loaded onto the gel. After
electrophoresis the gel was stained with Coomassie
brilliant blue R-250.
Determination of the molecular mass of WSG was
also carried out by gel filtration according to the method
of Andrews [28].
Detection of glycoprotein by periodic acid Schiffs (PAS)
staining
SDS–PAGE was carried out in slab gels as described
above. PAS staining was done according to the method
of Leach et al. [29].
Gas–liquid chromatography (GLC). The WSG, (4mg)
in 1ml of trifluroacetic acid (2N) was taken in a sealed
tube. Hydrolysis was carried out at 100 C for 6–8 h in an
oven. Acid in the hydrolysate was removed by flash
evaporation in a water bath at 40 C and codistilled with
water (1ml 3). The hydrolyzed sample was passed
throughDowex 1/50 ion-exchangers to remove the amino
acids. The neutralized and deionized sample was con-
centrated to 0.5ml and subjected to preparation of alditol
acetate derivative by themethod of Sawardekar et al. [30].
A Shimadzu GLC (Model CR4 A) fitted with a flame
ionization detector was used for analysis. OV-225 was the
column used with a column injector and detector block.
The temperature was maintained at 200, 225, and 250 C.
Nitrogen at a flow rate of 40ml/minwas used as the carrier
gas. The GLC–MS analysis of the sample was carried out
as described by Jansson et al. [31]. The analysis was car-
ried out on a Shimadzu GLC (Model QP 5000) using an
SP 2380 capillary column.A temperature gradient of 180–
200 C with an increase of 4 C/min was maintained for
analysis, ionization potential was 70 eV, and mass range
(m/z) was 40–400. Helium was the carrier gas used.
Interaction of WSG with NN–XIa–PLA. The incu-
bated mixtures of NNXIa–PLA with WSG (1:1, w/w)
and NNXIa–PLA and WSG were separately loaded
onto a Sephadex G-50 column (1 50cm) preequili-
brated with PBS. Two-milliliter fractions were collected
at a flow rate of 20ml/h. Fractions were screened in a
spectrophotometer at 280 nm.
Cytotoxicity determination. Cytotoxicity was deter-
mined using Ehrlich ascites tumor (EAT) cells grown in
Fig. 1. Purification of WSG fromWithania somnifera. (A) Sephadex G-
50 column chromatography of root extract ofW. somnifera. The column
(1:4 73cm), equilibrated with 0.1M NaCl was loaded with 180mg of
root extract of W. somnifera in the same buffer. (B) Fractionation on
DEAE–Sephadex A-25 column. The column (1:4 35cm) equilibrated
with 0.01M Tris–HCl buffer (pH 6.0) was loaded with 32mg of WSI
fraction. Elution was carried out stepwise with 0.01M Tris–HCl buffer
(pH 6.0) at various molarities of NaCl as indicated at 20 C. (C) Re-
chromatography of WD3 on DRAE–Sephadex A-25 column. The col-
umn (1:4 50cm) equilibrated with 0.01M Tris–HCl buffer (pH 6.0)
was loaded with 8mg ofWD3 fraction. Elution was carried out stepwise
with 0.01M Tris–HCl buffer (pH 6.0) at various molarities of NaCl as
indicated at 20 C. Protein elution was monitored at 280 nm.
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the peritoneal cavity of Swiss albino mice as described
by Chwetzoff et al. [32]. EAT cells were suspended in
Tyrodes Ringer buffer (5 106 cells/2ml) and incubated
with NNXIa–PLA alone and NNXIa–PLA/WSG (0.5–
2.0M/M) for 30min. Trypan blue saline (1%, 100 ll)
solution was then added, and unstained (viable) cells
were counted using a hemocytometer. The percentage of
viable cells was determined by comparing the number of
viable cells in control as 100%.
Edema-inducing activity. Edema-inducing activity was
assayed according to the method of Yamakawa et al.
[33]. NNXIa–PLA was incubated with various molar
concentrations of the glycoprotein WSG (0.5–2M/M) in
20 ll of saline for 1 h at 37 C. The incubated mixture
was injected into the right footpad of the hind limb of
mice (in groups of four to six) and 20 ll of saline in the
left footpad of the hind limb. Control experiments were
performed by injecting NNXIa–PLA alone. The in-
crease in weight due to edema was calculated as the
edema ratio, which equals the weight of edematous leg
100/weight of normal leg.
Myotoxicity determination. NNXIa–PLA (half LD50
dose) in 0.3ml of PBS was incubated with WSG (1:2M/
M) for 1 h at 37 C prior to injection (i.m) of the mixture
into groups of five mice. After 2 h, the mice were anes-
thetized with diethyl ether. The abdominal cavity was
opened and blood was collected from the abdominal
vena cava. Creatine phosphokinase (CPK) and lactate
dehydrogenase (LDH) levels were determined in the
serum by using the Span diagnostic kit. Control exper-
iments were performed by injecting saline solution
containing the WSG alone under similar conditions.
Activity was expressed as IU/liter. The mice were in-
jected with either NNXIa–PLA (30 lg in 50 ll of saline)
or mixtures of NNXIa–PLA and WSG separately into
the thigh muscle. Control mice received PBS alone or
WSG. All the animals were anesthetized with diethyl
ether 3 h after injection and sacrificed; the muscle
around the site of the injection was removed fixed in
40% formaldehyde for 2–3 days. The sections were
stained with Miligans trichrome stain [34].
Modification of histidine residue by p-bromophenacyl
bromide (p-BPB). Modification of histidine residue was
carried out as described by Diaz-Oreiro and Gutierrez
[35]. Briefly, 3mg of NNXIa–PLA was dissolved in 1ml
of 0.1M Tris–HCl buffer, pH 8.0, containing 0.7mM
EDTA and 125 ll of p-BPB solution (1.5mg/ml in etha-
nol) was added and incubated at 25 C for 24 h. Excess
reagent was removed by gel filtration on a SephadexG-25
column (1 15cm) by eluting with distilled water at a
flow rate of 1ml/min. Then the protein peak was pooled
and lyophilized. The modified NNXIa–PLA was char-
acterized for its cytotoxicity, edema, andmyotoxic effects.
Statistics. All values presented are means SE sta-
tistical analyses were done by Students t test. A P value
of less than 0.01 was considered significant.
Results
Purification of WSG
The W. somnifera extract resolved into two peaks,
WSI and WSII, in gel-permeation chromatography on
Sephadex G-50 (Fig. 1A). WSI accounted for 17.7% of
the total protein and WSII (62.2%) the remaining. The
WSI inhibited the PLA activity of NNXIa–PLA and
was further subjected to fractionation on the DEAE–
Sephadex A-25 column. The WSI resolved into five
peaks (Fig. 1B). The WD3 upon rechromatography
on DEAE–Sephadex A-25 column resolved into two
peaks, WSG and WSG1 (Fig. 1C). The WSG exhibited
maximum inhibitory activity on NNXIa–PLA and was
further characterized. WSG eluted as a single peak on
RP-HPLC (Fig. 2) with a retention time of 20min.
Characterization of WSG
WSG showed a single band, whereas the crude extract
andWSI showed a number of bands on PAGE (Fig. 3A).
Similarly on subjecting crude extract, WSI, WSG, and
protein molecular weight markers to SDS–PAGE under
reduced condition,WSG gave a single band whereasWSI
and crude extract gave several bands (Fig. 3B). The mo-
lecular weight of WSG was found to be 22.5 kDa by gel
filtration and 27 kDa by SDS–PAGE. The WSG gave a
single positive pink colored band on PAS staining (Fig. 2,
inset). The carbohydrate contents of crude extract, WSI,
andWSG are given in Table 1. WSG is composed of 23%
carbohydrate, the protein–carbohydrate ratio being
1:0.3. Amino sugars contributed to 33% of the total car-
bohydrate in WSG (Table 1). The sugar composition of
WSG revealed substantial amounts of glucose, galactose,
and mannose along with other sugars like arabinose, xy-
lose, rhamnose, and fucose. The percentage composition
of each sugar calculated from the GC–MS profile is given
in Table 2. Phenolic compounds were absent inWSG but
were found in crude extract and in WSII (Table 1).
Gel-permeation chromatography on Sephadex G-50 col-
umn
The NNXIa–PLA, the WSG, and the interacted
NNXIa–PLA with WSG in PBS (1:1, w/w) eluted at dif-
ferent elution volumes. Each of the them eluted as a single
discrete peak. The NNXIa–PLA eluted at an elution
volume of 38ml,WSGat 34ml, and the interacted sample
at 20ml. The elution of the interacted sample occurred
before the elution of the individual components (Fig. 4).
Antitoxic properties of WSG
WSG completely neutralized the PLA activity of
NNXIa at a ratio of 1:2 (M/M). NNXIa–PLA exhibited
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cytotoxicity onEAT cells.WSG inhibited the cytotoxicity
in a dose-dependent manner and complete neutralization
was observed at a concentration of 1:2 (M/M) (Fig. 5A).
The edema-inducing activity of NNXIa–PLA was
effectively inhibited by WSG fraction in a dose depen-
dent manner (Fig. 5B). Complete neutralization was
observed at a concentration of 1:2M/M.
The myotoxicity was confirmed by measuring plasma
CPK and LDH activities that resulted in drastic in-
creases of the activities at 2 h in comparison with control
mice receiving PBS alone. WSG neutralized the myo-
toxicity induced by NNXIa–PLA completely at a molar
ratio of 1:2 (PLA:WSG) as evidenced by the normal
CPK and LDH values observed in the experimental
animals (Fig. 5C). The result is confirmed by histo-
pathological studies, which exhibited complete neutral-
ization of myonecrosis with release of only a few
inflammatory cells (Fig. 6).
Fig. 2. Reverse-phase HPLC analysis of WSG. WSG (20 lg) was applied on to a Shim-Pak (ODS) C18 (10lm, 0:46 25cm) column equilibrated
with 0.1% TEA in water. Separation was achieved by a linear gradient of (0–100%) acetonitrile in 0.1% TEA. The flow rate was 1ml/min and the
elution profile was monitored at 280 nm. (Inset) PAS staining.
Fig. 3. (A) PAGE of crude extract (1), WSI (2), WD3 (3), and WSG (4) were loaded on 10% polyacrylamide gel and run at pH (8.8) using Tris–glycine
buffer. The gel was run at 20mA for 3 h. (B) SDS–PAGE pattern of crude (1), WSI (2), WSG (3), and low-molecular-weight markers (M) under
reduced conditions on 12.5% gel. Molecular weight markers from top to bottom are in kilodaltons: ovalbumin (45), carbonic anhydrase (29), trypsin
inhibitor (20), a-lactalbumin (14.2), and aprotinin (6.5).
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Fig. 5. Neutralization of pharmacological effects of NNXIa–PLA by
WSG. Effect of increasing molar concentration of WSG on (A) cyto-
toxicity, (B) edema-inducing activity, and (C) myotoxicity (j, CPK
activity; , LDH activity) of NNXIa–PLA. Values represent mean-
sSE (n ¼ 5). *P < 0:01, when compared to NNXIa–PLA activity.
Fig. 4. Interaction of NNXIa–PLA and WSG. Gel filtration of (N)
NNXIa–PLA () WSG and (d) preincubated NNXIa–PLA and WSG
on a Sephadex G-50 column. The column (1 50cm) was pre equili-
brated with phosphate-buffered saline (PBS) 0.1M, pH 7.4. The sam-
ples were loaded separately and eluted with the same equilibrating
buffer. Fractions of 2ml were collected at a flow rate of 20ml/h at
room temperature. Protein elution was monitored at 280 nm.
Table 1
Composition of extracts and WSG
Total Protein (mg) Total carbohydrate (mg) Protein:carbohydrate Amino sugars (mg) Phenols (mg)
Crude 180 25 1:0.14 8.6 56
Sephadex G-50
WSI 32 6 1:0.19 1.2 Nil
WSII 112 16 1:0.14 3.3 48
WD3 6.3 1.69 1:0.19 0.68 Nil
WSG 2.1 0.840 1:0.3 0.28 Nil
Table 2
Composition of sugar as determined by GC–MS of WSG
Sugars (%)
Glu Gal Man Xyl Ara Rham Fuc
WSG 25 19.2 16.3 12.2 12.2 8.1 7.3
M. Deepa, T. Veerabasappa Gowda / Archives of Biochemistry and Biophysics 408 (2002) 42–50 47
Modification studies
Modification of the histidine residue of NNXIa–PLA
with p-bromophenacyl bromide resulted in the loss of
catalytic, cytotoxic, edema, and myotoxic activities.
Discussion
A number of plant extracts have been reported to
possess detoxifying effects on snake venoms [3,8,11].
Though there are a number of reports on plants from
different geographical areas, which neutralize the toxicity
of snake venom, only a few attribute such activity to the
identified chemical compounds. Wedelolactone was
shown to exert several well-defined pharmacological ac-
tivities such as antimyotoxic, antihemorrhagic and anti-
proteolytic [36–38]. Among the purified components
stigmasterol, sitosterol, flavonoids, glycosides, caffeic
acid, and coumarins are common constituents of plants
like Eclipta prostrata, Alpinia speciosa, and Schumanni-
ophyton magnificum which exhibit anti-snake-venom ac-
tivity [7]. The action of the extracts on neutralization of
snake venom is attributed to the presence of more than
one active compound. The identified active substances
aremostly low-molecular-weight compounds that exhibit
more than one biological or pharmacological property in
addition to an antidotal effect. To mention a few, caffeic
acid, curcumin, flavonoids, and their derivatives possess
antiinflammatory, hepatoprotective, and anticarcino-
genic activities. Mors et al. [7] has observed a striking
parallelism between the capability of plants and their
chemical components, which are antiinflammatory and
antihepatotoxic as well as neutralizing the snake venom
toxicity. The extracts of W. somnifera are reported to
contain Withanolides, Withanolide glycosides, C-28 ste-
roid lactones, saccharose, b-sitosterol, and macromole-
cules [39–41]. Most of the compounds noted above have
structural similarities to compounds mentioned earlier
and also possess antiinflammatory, antihepatotoxic, and
immunomodulatory activities [18–21]. These compounds
derived from plants structurally resemble secondary
metabolites, which is the basis for their physiological
action [10]. Despite identifying several active compounds
from plant isolates only a few studies explain the mech-
anism of action of the compound.With the aid of circular
dichorism studies Vishwanath et al. [42] found that aris-
tolochic acid forms a 1:1 complexwith PLA2, acting like a
noncompetitive inhibitor of the toxic PLA2. Tsai et al.
[43] demonstrated the association between aristolochic
acid and PLA2 that resulted in significant change in the
secondary structure of the enzyme. Wedelolactone in-
hibits myotoxicity of CVV myotoxin from Crotalus viri-
dis viridis, bothropsin from Bothrops jararacus, and ACL
myotoxin from Akistrodon contortrix laticinctus venoms
by binding to toxins. Studies carried out by Melo and
Ownby [38] have demonstrated that polyanions like
chondroitin sulfate and heparin bring about the neu-
tralization of the myotoxicity of Bothrops venom partly
by nonspecific acid–base complex formation and partly
due to more specific interaction with the proteins.
The macromolecular fraction fromW. somnifera root
extract inhibited the phospholipase activity of the Indian
cobra N. naja venom and also increased the survival
time of mice injected with the lethal dose of the venom.
In contrast the micromolecular fraction enhanced the
PLA activity.
Characterization of glycoprotein WSG
WSG, a glycoprotein, was isolated from the roots of
W. somnifera by subjecting it to buffer extraction fol-
lowed by gel-filtration and ion-exchange chromatogra-
phy. A number of phenolic compounds are known to be
associated with plant extract, for example, hydroxy
benzoic acid, flavonoids, tannins, and coumarins
[7,10,44]. The phenol and phenolic derivatives were ex-
cluded during the purification step and hence the gly-
coprotein was free of phenols. Molecular mass
determined by the two methods varied 22.5 kDa by gel
filtration and 27 kDa by SDS–PAGE. We have used the
higher molecular mass for all calculations. The compo-
sition of sugars by GC–MS showed larger proportions
Fig. 6. Light micrograph of longitudinal sections of thigh muscle of
mice (40) after im injection: (A) control, (B) NNXIa–PLA, and (C)
NNXIa PLA and WSG at 1:2M/M ratio. Widespread necrotic cells
(M), inflammatory cells (I), and disorganized nuclei are observed in
(B).
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of hexoses (61%) and lower proportions of pentoses,
which comprised the remaining (39%) (Table 2). A flu-
orescence emission maximum was found to be at
342 nm, indicating the presence of exposed tryptophan
residues in the molecule (data not shown).
Several glycoprotein inhibitors of snake venom
PLA2s have been isolated from the blood plasma of
venomous and nonvenomous snakes [45–48]. They are
invariably acidic a-globulins that inactivate PLA2 by
forming soluble complexes. In addition to their anti-
PLA2 properties, some of these factors also neutralize
the toxic effects induced by a particular PLA2. CgMIP-I
and CgMIP-II purified from blood plasma inhibited the
myotoxicity of the two variants enzymatically active
(myotoxin I) and inactive, Lys-49 (myotoxin II), isolated
from Cerophidian godmani [49]. Six phospholipase in-
hibitors (PLIs) isolated from a range of Australian ela-
pid sera, were able to protect in vivo the lethal effects of
homologous PLA2 [50]. The PLIs are generally com-
posed of two protein chains, an a-chain and a b-chain.
The a-chains are 20- to 30-kDa glycoprotein subunits
and the b-chains are nonglycosylated 20- to 25-kDa
protein subunits. The carbohydrate moiety is found not
to effect the in vitro function of the inhibitor [50,51]. The
WSG is also an acidic glycoprotein similar to the a-
chain of the PLIs but in contrast it is composed of a
single protein. Carbohydrate moieties did not contribute
to the inhibitory activity of the catalytic and the myo-
toxic effects of the NNXIa–PLA.
Melo and Ownby [38] used gel filtration to demon-
strate the complex formation between heparin and a
myotoxic PLA from B. jararacussu venom. This is evi-
dent by the increased molecular mass of 37 kDa (equal to
1:1 complex between glycoprotein and NNXIa–PLA)
observed by gel filtration (Fig. 4). The displaced move-
ment of the associated protein may be considered as
proof of association. The association appears to be due
to electrostatic interactions between the negatively
charged groups of acidic glycoprotein and the positive
charge of basic phospholipase. The interacted complex
could not be cited on the electrophoresis. However, such
an electrostatic association of glycoproteinWSGwas not
found with a basic PLA2 NNXIII and VRV-PL-VIIIa
from N. naja and Vipera ruselii venoms, respectively
(data not shown). Therefore, the electrostatic interaction
of the glycoprotein and PLA2 may also require specific
basic residues in a specific conformation site.
Neurotoxic NNXIa–PLA is toxic to EAT cells and
also induces edema, and myotoxicity in mice. WSG
neutralized both cytotoxicity and edema induced by
NNXIa–PLA2 in a dose-dependent manner. One of the
mechanisms by which PLA2s induced edema is by re-
lease of lysophosphotides and fatty acids [52]. However,
enzyme activity is not strictly required to induce this
effect [53]. Caseria sylvestris is known to inhibit the
edema induced by B. jararaca [54]. Elaerodendron balae
root extract, used to cure swelling, is also effective
against snakebite toxicity [8].
Venoms from snakes of several different families cause
myonecrosis. Homma and Tu [55] divided the muscle cell
necrosis produced by 37 venoms into three types based on
histological features. These groups were designated as (1)
coagulation type, (2) myolysis type, and (3) mixed type,
which consists of both of the types in equal numbers.
Generally, elapid venoms exhibit the second type of
myonecrosis due to the presence of either myotoxic
phospholipases or cardiotoxins in the venoms. Ownby
and Colberg [56] noted that the N. naja venom-induced
myonecrosis observed was similar to that induced by the
phospholipase myotoxins such as notexin, taipoxin,
crotoxin, and Bothrops species myotoxins [57–61]. Nu-
merous specific toxic phopholipase A2s have been iso-
lated from elapid venoms likePseudechis australis venom.
PLA2s Pa-IG, Pa-5, Pa-12, and Pa-15 are characterized
as being homologous single-chain postsynaptically acting
basic PLA2s (with the exception of Pa-IG which is un-
iquely acidic) that damage muscle fibers resulting in loss
of muscle contractility [62]. The myotoxicity induced by
NNXIa–PLA is the myolysis type. Histopathological
studies support the myolysis type myotoxicity. The WSG
completely neutralized the myonecrotic activity of the
NNXIa–PLA supported by the significant inhibition of
serum LDH and CPK value of the NNXIa–PLA and the
integrated muscle. Myonecrosis following snake enven-
omation is due to the presence of phospholipase myo-
toxins, hence the neutralization may be achieved by
antienzyme action to inhibit the myotoxic PLA2 in ve-
nom [7,38]. Fukami and Hattori [63] reported that per-
simmon tannin inhibited completely the necrotic lesions
induced by habu, mamushi, and cobra venom. Crude
extract of Eclipta prostrate and its three active com-
pounds wedelolactone, sitosterol and stigmasterol
showed antagonism against myotoxic effects of Bothrops
venom [8,38]. WSG neutralized the cytotoxicity, edema,
and the myotoxic effects induced by NNXIa–PLA. WSG
inhibited the PLA activity at a molar ratio 1:2 (Data not
shown) as well as neutralized the pharmacological effects
of the PLA at the same molar ratio. The catalytic histi-
dine-modified NNXIa–PLA was devoid of cytotoxicity,
edema inducing activity and myotoxic effects. Therefore
all the three pharmacological effects appear to depend on
the PLA activity of the toxin. However, the neurotoxic
effect of the PLA is not neutralized by WSG, while
histidine-modified PLA failed to induce any neurotoxic
effects. Modification of active site histidine by p-brom-
ophenacyl bromide converts a neurotoxic PLA into non
neurotoxic protein. WSG fails to transform a neurotoxic
PLA into a non-neurotoxic PLA due to its weak elec-
trostatic interaction with the toxin.
WSG a glycoprotein similar to a-proteins of snake
serum is purified and characterized from W. somnifera.
Interaction of WSG with multitoxic N. naja PLA
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suggests that WSG appears to confer beneficial effects
against snake venom toxicity. Further antivenom
properties of this molecule are being investigated.
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